1046 related articles for article (PubMed ID: 32081779)
1. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
2. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
3. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy.
Yang Y; Lu X; Liu Q; Dai Y; Zhu X; Wen Y; Xu J; Lu Y; Zhao D; Chen X; Li N
Eur J Pharm Sci; 2017 Jul; 105():219-229. PubMed ID: 28526602
[TBL] [Abstract][Full Text] [Related]
4. Liposomal Doxorubicin: the Sphingomyelin/Cholesterol System Significantly Enhances the Antitumor Efficacy of Doxorubicin.
Meng X; Zhang H; Chen L; Wang M; Zhang K; Liu X; Deng Y; Song Y
AAPS PharmSciTech; 2023 Feb; 24(2):64. PubMed ID: 36759405
[TBL] [Abstract][Full Text] [Related]
5. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy.
Thomas E; Menon JU; Owen J; Skaripa-Koukelli I; Wallington S; Gray M; Mannaris C; Kersemans V; Allen D; Kinchesh P; Smart S; Carlisle R; Vallis KA
Theranostics; 2019; 9(19):5595-5609. PubMed ID: 31534505
[TBL] [Abstract][Full Text] [Related]
7. Tumor-permeable smart liposomes by modulating the tumor microenvironment to improve the chemotherapy.
Widjaya AS; Liu Y; Yang Y; Yin W; Liang J; Jiang Y
J Control Release; 2022 Apr; 344():62-79. PubMed ID: 35182612
[TBL] [Abstract][Full Text] [Related]
8. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
[TBL] [Abstract][Full Text] [Related]
9. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
10. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma.
Xiao K; Luo J; Li Y; Lee JS; Fung G; Lam KS
J Control Release; 2011 Oct; 155(2):272-81. PubMed ID: 21787818
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
13. Photosensitizer-Doped and Plasma Membrane-Responsive Liposomes for Nuclear Drug Delivery and Multidrug Resistance Reversal.
Zhu YX; Jia HR; Duan QY; Liu X; Yang J; Liu Y; Wu FG
ACS Appl Mater Interfaces; 2020 Aug; 12(33):36882-36894. PubMed ID: 32666795
[TBL] [Abstract][Full Text] [Related]
14. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
[TBL] [Abstract][Full Text] [Related]
15. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
Ling L; Ismail M; Du Y; Yao C; Li X
Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
[TBL] [Abstract][Full Text] [Related]
16. [Physicochemical Property of iRGD Peptide Modified Doxorubicin Loaded Liposome and Its Effect on Cancer Cell Growth].
Zhang ZQ; Zhong CL; Zhao X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Nov; 46(6):837-41. PubMed ID: 26867317
[TBL] [Abstract][Full Text] [Related]
17. Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer.
Shmeeda H; Amitay Y; Gorin J; Tzemach D; Mak L; Stern ST; Barenholz Y; Gabizon A
J Drug Target; 2016 Nov; 24(9):878-889. PubMed ID: 27187807
[TBL] [Abstract][Full Text] [Related]
18. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
[TBL] [Abstract][Full Text] [Related]
19. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
20. Cationic Polymethacrylate-Modified Liposomes Significantly Enhanced Doxorubicin Delivery and Antitumor Activity.
Wang W; Shao A; Zhang N; Fang J; Ruan JJ; Ruan BH
Sci Rep; 2017 Feb; 7():43036. PubMed ID: 28225062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
